PLIANT THERAPEUTICS, INC. (PLRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of PLRX. The 7-day demo opens the 1M and 3M ranges and puts PLRX on your watchlist.
Start 7-day demoLatest PLRX insider trades
- Keith Lamont Cummings - OfficerOpen-market sale$31K
Lily Cheung - OfficerOpen-market sale$10K
About PLIANT THERAPEUTICS, INC. (PLRX)
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
- SOUTH SAN FRANCISCO, CA
- 49
- 2020
- XNAS
PLRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 575,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PLRX insider transactions (Form 4)
5923 Form 4 filings on record, the earliest from Jun 5, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 David Raben - Officer | Grant or award | Stock Option (Right to Buy) | 575,000 | $0.00 | - | |
| Robert Iannone - Director | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| Flavia Borellini - Director | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| Gayle A. Crowell - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
 Thomas A. McCourt - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
 Steve E. Krognes - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
 John T. Curnutte - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Hoyoung Huh - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Darren S. Cline - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Minnie Kuo - Officer | Derivative | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Minnie Kuo - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Minnie Kuo - Officer | Derivative | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Minnie Kuo - Officer | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Minnie Kuo - Officer | Derivative | Stock Option (Right to Buy) | 55,200 | $0.00 | - | |
| Minnie Kuo - Officer | Grant or award | Stock Option (Right to Buy) | 55,200 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 76,047 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 76,047 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 18,198 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 18,198 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 74,250 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 74,250 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 124,000 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 124,000 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 76,200 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 76,200 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 110,500 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 110,500 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Derivative | Stock Option (Right to Buy) | 113,300 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 113,300 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 146,841 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 146,841 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 327,262 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 327,262 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 250,000 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 440,000 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 440,000 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 206,300 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 206,300 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 256,300 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 256,300 | $0.00 | - | |
| Bernard Coulie - Officer | Derivative | Stock Option (Right to Buy) | 325,000 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 325,000 | $0.00 | - | |
| Lily Cheung - Officer | Derivative | Stock Option (Right to Buy) | 123,000 | $0.00 | - | |
| Lily Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 123,000 | $0.00 | - | |
| Lily Cheung - Officer | Derivative | Stock Option (Right to Buy) | 52,000 | $0.00 | - | |
| Lily Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 52,000 | $0.00 | - | |
| Lily Cheung - Officer | Derivative | Stock Option (Right to Buy) | 51,750 | $0.00 | - | |
| Lily Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 51,750 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | $0.00 | - | |
| Minnie Kuo - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Lily Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Bernard Coulie - Officer | Grant or award | Stock Option (Right to Buy) | 1,230,000 | $0.00 | - | |
| Keith Lamont Cummings - Officer | Open-market sale | Common Stock | 24,002 | $1.28 footnote F1 | $31K | |
| ||||||
| Lily Cheung - Officer | Open-market sale | Common Stock | 7,534 | $1.28 footnote F1 | $10K | |
| ||||||
| Bernard Coulie - Officer | Open-market sale | Common Stock | 89,375 | $1.28 footnote F1 | $114K | |
| ||||||
| Minnie Kuo - Officer | Open-market sale | Common Stock | 6,917 | $1.28 footnote F1 | $9K | |
| ||||||
| Gayle A. Crowell - Director | Grant or award | Common Stock (Right to Buy) | 30,000 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Common Stock (Right to Buy) | 30,000 | $0.00 | - | |
Item 2.02, 9.01
Item 5.02
Item 5.07
Item 2.02, 9.01
PLRX insider trading FAQ
What is the latest insider trade for PLRX?
PLIANT THERAPEUTICS, INC. (PLRX) had 1 insider filing in the last 90 days, with the most recent on 2026-10-02. The full record for PLRX runs to 23 Form 4 filings, the earliest from 2025-06-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PLRX stock?
No insider purchases of PLRX were filed in the last 90 days.
How many insiders are selling PLRX stock?
No insider sales of PLRX were filed in the last 90 days. 4 sales are on record for this company.
Where can I see PLRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PLRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David Raben view on EDGAR
- - Robert Iannone view on EDGAR
- - Flavia Borellini view on EDGAR
- - Gayle A. Crowell view on EDGAR
- - Thomas A. McCourt view on EDGAR
- - Steve E. Krognes view on EDGAR
- - John T. Curnutte view on EDGAR
- - Hoyoung Huh view on EDGAR
- - Darren S. Cline view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PLRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PLRX with a 7-day demo
- PLRX on your watchlist
- Every PLRX Form 4 filing on record
- Up to 3 months of PLRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
